The pathway from the onset of symptoms to diagnosis and then initial treatment is often lengthy and complex. In some low and middle-income countries (LMICs) like Bangladesh, the mean time between the initial onset of lung cancer symptoms and confirmation of diagnosis can approximately be 151 days from first contact with an informal care team such as pharmacy retailers, village doctors, and traditional healers or formal care team.1 Beyond the impact on clinical outcomes, delays in diagnosis also have emotional and psychological impacts and these are shown to positively correlate with the duration of the delay.2
The final of our Ambition Improvement Measurement (AIM) reports: ‘Optimising Access to Care Through Timely Referral Pathways, highlights staggering statistics like this and calls for more rapid lung cancer diagnosis and treatment to increase survival rates and equalize lung cancer patient pathways globally. Our goal for people experiencing symptoms is a rapid referral pathway that decreases the wait time to a maximum of two weeks from the referral of a General Practitioner (GP) to the lung cancer assessment appointment with a hospital specialist.3,4 The report identifies stigma as one of the key barriers to timely lung cancer diagnosis and calls to challenge these preconceptions through improved education and awareness of patients and healthcare professionals (HCPs).5
In addition to stigma, the report further explores global health inequity that is delaying diagnoses and proper care for people affected by lung cancer, which is felt even more acutely by people in LMICs. These challenges often present in the form of inadequate technology and infrastructure, which undercuts health systems’ ability to provide a timely diagnosis.5 Further based on a patient’s country or region, their access to diagnosis and treatment care may be more limited due to factors wholly outside of the healthcare system, such as public infrastructure challenges like poor road conditions, lack of transportation, and long commute times.6,7 Even when patients and their caregivers can get to a clinic for diagnosis and/or treatment, there may still be further setbacks presented by a lack of a skilled workforce and staff shortages.6,7
The social and economic burden of lung cancer is most heavily felt in LMICs where lung cancer disproportionality affects people living in socio-economically deprived communities.8,9 Finally, accessibility and affordability of new treatments are still major barriers to access to care and a timely referral process.10 LMICs currently have less than 5% of the estimated share of global resources for combatting cancer, and affordability remains a significant obstacle to treatment in countries with limited government reimbursement of medicines or reduced funding for radiotherapy treatment centers.10
Intended for policymakers at any level worldwide, the report provides the following four recommendations and corresponding methods to improve the coordination and timeline of referrals:
1. Improving patient and healthcare team awareness
- Sample recommendation: increase general patient education using simple tools that patients can relate to e.g., treatment plan summaries.
- Related measurement opportunity: percentage of patients receiving educational resources.
2. Improving infrastructure and capacity
- Sample recommendation: using future technologies and artificial intelligence (AI) can lower the cost and aid diagnosis while supporting the HCP/patient interface.
- Related measurement opportunity: new technologies implemented at a national level.
3. Defining the pathway and supporting effective navigation
- Sample recommendation: develop guidelines that effectively cover the whole testing pathway with relevant consultation across all applicable sectors.
- Related measurement opportunity: median waiting time between the suspicion and diagnosis of lung cancer and between the first referral of GP and the hospital treatment initiation
4. Improving access to therapies
- Sample recommendation: develop an updated and revised evidence-based national essential medicines list (NEMLs) that responds to a country’s needs.
- Related measurement opportunity: number of new therapies available globally and the reduction in the cost of treatment.
The optimisation of rapid referrals is possible, but policy and decision-makers need to evaluate and act upon these recommendations which reflect the diverse perspectives and experiences of healthcare providers, patient group representatives, researchers, and industry partners as convened by the LAA and its AIM program. Our goal, to consistently deliver the best possible lung cancer care across treatment networks around the world, is more urgently needed than ever. We hope this white paper series provides practical guidelines for health systems and policymakers that will improve lung cancer diagnoses, treatment, and outcomes for anyone impacted by this disease.
Explore our other AIM white paper reports in this series:
Find out more about the Lung Ambition Alliance and its overarching mission:
References:
1 Ansar A, Lewis V, McDonald CF, et al. Duration of intervals in the care seeking pathway for lung cancer in Bangladesh: A journey from symptoms triggering consultation to receipt of treatment. PLOS ONE. 2021. 16(9): e0257301.
2 Bjerager M, Palshof T, Dahl R, Vedsted P, Olesen F. Delay in diagnosis of lung cancer in general practice. Br J G Pract.. 2006. 56(532):863–868. Available at: https://pubmed.ncbi.nlm.nih.gov/17132354/. Accessed July 2023.
3 Macmillan Cancer Support. Lung and pleural cancer referral guidelines. Available at https://www.macmillan.org.uk/healthcare-professionals/cancer-pathways/prevention-and-diagnosis/rapid-referral-guidelines/lung-cancer Accessed July 2023.
4 Wiering B, Lyratzopoulos G, Hamilton W, et al. Concordance with urgent referral guidelines in patients presenting with any of six ‘alarm’ features of possible cancer: a retrospective cohort study using linked primary care records. BMJ Quality & Safety. 2022;31:579-589.
5 Optimising Access to Care Through Timely Referral Pathways. Lung Ambition Alliance. Available at: https://www.lungambitionalliance.com/News.html Accessed: July 2023
6 Edelman Saul E, Guerra RB, Edelman SaulM, et al. The challenges of implementing low-dose computed tomography for lung cancer screening in low- and middle-income countries. Nature Cancer. 2020. 1:1140–1152.
7 Irving G, Neves AL, Dambha-Miller H, et al. International variations in primary care physician consultation time: a systematic review of 67 countries. BMJ Open. 2017. 7(10):1-15.
8 Ellis P, Vandemeer R. Delays in the diagnosis of lung cancer. J Thorac Dis. 2011. 3(3);183–8.
9 Lubuzo B, Ginindza T, Hlongwana K. The barriers to initiating lung cancer care in low-and middle-income countries. Pan Afr Med J. 2020 Feb 12;35:38. doi: 10.11604/pamj.2020.35.38.17333. PMID: 32499854; PMCID: PMC7245978.
10 Mattila PO , Ahmad R, Hasan SS, et al. Availability, affordability, access, and pricing of anti-cancer medicines in low- and middle-income countries: a systematic review of literature. Front Public Health. 2021. 9:628744.
11 Ning J, Ge T, Jiang M, et al. Early diagnosis of lung cancer: which is the optimal choice? Aging. 2021. 13(4):6214-6227.
Date of Preparation: Aug 2023 | Document ID: Z4-56901